GlassScriptPhysician profile
David M Shein
NPI 1548218712
$3,929.16
in general payments reported to CMS, 2019-2025
27 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $535 · 2021: $593 · 2022: $606 · 2023: $206 · 2024: $368 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $772.38 | 2019-2025 | |
| Abbvie INC. | $543.85 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $398.14 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $315.44 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $266.55 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $250.10 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals LP | $221.52 | 2019-2024 | Farxiga, Breztri |
| E.R. Squibb & Sons, L.L.C. | $199.81 | 2019-2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.58 | 2019-2023 | Jardiance |
| Amgen INC. | $157.87 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $113.29 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $103.71 | 2019 | |
| Therapeuticsmd, INC. | $46.03 | 2019 | |
| Sanofi Pasteur INC. | $39.96 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.26 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $38.48 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $35.51 | 2019 | |
| Endo Pharmaceuticals INC. | $30.86 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $26.09 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.95 | 2022 | |
| Exact Sciences Corporation | $24.58 | 2025 | Cologuard Collection Kit |
| Medtronic, INC. | $21.36 | 2024 | Closurefast |
| Shield Therapeutics INC | $21.05 | 2024 | |
| Bausch Health US, LLC | $18.25 | 2021 | |
| Valeritas, INC. | $17.96 | 2019 | |
| Corium, LLC | $17.17 | 2022 | |
| Glaxosmithkline, LLC. | $16.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.